RAC 2.20% $1.78 race oncology ltd

Ann: Race Strategic Update March 2021, page-382

  1. 2,725 Posts.
    lightbulb Created with Sketch. 10538
    The problem with taking the Pandion approach is unlike Pandion is we don’t have a register dominated by biotech VC funds who will hold out for a better deal. For better or worse RAC's registry is made up of Australian retail investors who have a history of selling out early for a minor premium.

    I want to see us get on with out clinical programs and once we have FTO data approach big pharma.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.